Сигурна ли е Sun Pharmaceutical Industries дивидентата?
Sun Pharmaceutical Industries увеличава дивидентата си от 5 години.
През последните 10 години Sun Pharmaceutical Industries ги е увеличил със средно 24,573 % годишно увеличен.
На 5-годишна база нарасна разпределението с 37,468 %.
Анализаторите очакват за текущата финансова година ръст от 1,244%.
Sun Pharmaceutical Industries Aktienanalyse
Какво прави Sun Pharmaceutical Industries?
Sun Pharmaceutical Industries Ltd is a leading company in the pharmaceutical industry, with its headquarters in Mumbai. The company was founded in 1983 by Dilip Shanghvi, a pharmacist who started with a capital of only 2000 rupees.
The company's history began with the manufacturing of psychotropic drugs. However, Sun Pharma quickly expanded into other areas, including dermatology, cardiology, pain medicine, and oncology. Over the years, the company has acquired many companies and established itself in the pharmaceutical industry through mergers and acquisitions. It has a market presence in the USA, Europe, Japan, Australia, and Africa.
Sun Pharmaceutical Industries Ltd's business model is based on the development and manufacturing of pharmaceuticals, generics, and biosimilars, as well as the provision of healthcare services. The company aims to provide innovative and affordable medicines to patients worldwide.
Sun Pharma is divided into various segments, including generic drug manufacturing, specialty pharmaceuticals, and its own developed oncology platform. In the generic drug manufacturing, Sun Pharma is considered one of the world's largest suppliers, covering a wide range of therapeutic areas. One of its most well-known segments is the manufacturing of nerve blockers and painkillers. In fact, Sun Pharma was the first Indian corporation to receive approval for an opioid painkiller in the United States.
Sun Pharmaceutical Industries Ltd offers a wide range of products, including:
1. Generics: The company is known for its cost-effective and high-quality generics, providing affordable treatment for a variety of diseases.
2. Biosimilars: Sun Pharma is also involved in the manufacturing of biosimilars, which has proven to be an important area.
3. Specialty pharmaceuticals: This segment includes a wide range of specialty pharmaceuticals, including medications for diabetes, asthma, and HIV treatment.
4. Oncology platform: Sun Pharma is focused on developing and marketing a wide range of oncology products, including cytostatics, immunotherapeutics, and cancer treatments.
Sun Pharmaceutical Industries Ltd has a wide network of research and development facilities in India and around the world. The company has acquired numerous patents and licenses to develop and market innovative drugs. A particular capability lies in developing complex technologies and techniques to offer cost-effective therapies.
In the past, Sun Pharma has faced some controversies, particularly related to the trading of opioids in the USA. However, the company has overcome these challenges and continues to focus on providing affordable and innovative medicines.
In summary, Sun Pharmaceutical Industries Ltd is a leading company in the pharmaceutical industry. With a wide range of products and services and a global presence, it is a significant player in the global market. The company remains dedicated to developing innovative and affordable drugs to meet the needs of patients worldwide. Sun Pharmaceutical Industries е една от най-популярните компании на Eulerpool.com.Акционерните спестовни планове предлагат привлекателен начин за инвеститорите да изградят дългосрочно богатство. Едно от основните предимства е така нареченият ефект на средната цена при покупка: като редовно се инвестира фиксирана сума в акции или акционерни фондове, автоматично се купуват повече дялове, когато цените са ниски, и по-малко, когато са високи. Това може да доведе до по-изгодна средна цена на дял във времето. Освен това акционерните спестовни планове позволяват дори на малките инвеститори да получат достъп до скъпи акции, тъй като могат да участват с малки суми. Редовната инвестиция също насърчава дисциплиниран подход към инвестирането и помага да се избегнат емоционални решения, като импулсивно купуване или продаване. Допълнително инвеститорите се възползват от потенциалното увеличение на стойността на акциите, както и от дивидентните изплащания, които могат да бъдат реинвестирани, усилвайки компаундиращия ефект и така растежа на инвестирания капитал.